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CHAPTER I

INTRODUCTION

Chemotherapeutic agents have been utilized in the treatment of
leukemia and transplantation studies with limited success .

The major

limiting factors are the toxic effects of the chemotherapeutic agents
and the immune response mechanism of the animal system.
Various antimetabolites are now available which are capable of
specifically inhibiting the innnune response.

These compounds act

primarily during the inductive period , (the interval between the
induction of antigen and the appearance of antibody) however, recent
evidence indicates possibly even during the proliferative phase
(Rosenthal , et a l. , 1968) .

Treatment of cancer patients with 6-MP

suppresses the antibody response to a primary antigenic stimulus,
pnevents the induction of delayed hypersensitivity and delayed
homografts rejections, but produces no significant changes in
established antibody levels .

This is important therapeutically

for is suppression of immunity were complete (as with X-Rays) the
patient becomes an immunological cripple, subject to the complications
of secondary infections (Dameshek, et al ., 1959).
Immunosuppressive agents like 6- MP attack vital steps in the
illllllune response, but they do it at least in part indi scr imimately and
damage all dividing cells to some degree ,

Thus the major side effect

of these immunosuppressants is their toxicity which makes it impossible for them to be used for long peri ods of time (Andre, 1962) .
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The toxicity of 6-MP has been well established in reports by Elion
et al. , 1962, 1954 and others.

Thus in an effort to reduce the toxic-

ity of 6-MP observed in homograft reaction studies with chicks, (Lewis
et al . , 1960) Palladium was complexed with pure 6-MP thus producing a
compound in which the hydrogen of the S-H group has been replaced with
sodium dichloropalladate II Monohydrate at the sixth carbon position of
the 6-MP molecule (Wei, 1960; Kirschner et al., 1966) .

According to

Sidgwick (1950) organic compounds with structures containing the S-H
group may accept platinum, palladium and some other metals by the direct
addition or replacement of the S-H hydrogen.

Si.nee 6- MP is metabolized

in the body to 6-thi.ouri.c acid (Hamilton and Eli.on 1954) it was felt
that alteration at the sixth position of 6-MP with the palladium metal
might result in eliminating or significantly reduced the toxicity.
Lewis et al., (1969) conducted experiments with chicks using the 6-MPPalladi.um complex which demonstrated less toxicity than the 6-MP ligand;
the less toxic effects were manifested in greater weight gain and lower
mortality in the 6-MP-Palladi.tnn complex treated chicks than occurred in
the 6-MP treated chicks.
The purpose of this investigation is to determine the uric acid
suppression capacity of 6-MP-Palladium complex in the sera and liver
of 6-MP treated chicks.
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CHAPTER II

REVIEW OF LITERATURE

In the search for antimetabolites, a wide variety of substances
have been tested over the years which have in common the property of
interfering with DNA and RNA synthesis and thereby preventing cell
division and new protein synthesis (Elion~ al., 1954).

The demon-

stration of drug-induced immunological tolerance by Dameshek and
Schwartz (1958) opened a new field for therapeutic application of
antimetabolites in nonneoplastic diseases.

6-MP, a nucleic acid anti-

metabolite and its complex, sodium dichloro-di-6-Mercaptopurinato
Palladate II Monohydrate have been found to be extremely active against
Adenocarcinoma 755 and Sarcoma 180 (Kirschner et al., 1966); Elion et
al., (1952) found that the substitution of a mercapto group in the
sixth position of the purine ring was a promising way of producing substances inhibitory to growth and whose action could be reversed by
administration of purines.
Uric acid levels in the blood and urine, are frequently elevated
in leukemia.

This condition is presumably derived in part from the

nucleic acids of the leukocytes and has been observed to increase
following effective radiation treatment, and in the administration
of Urethane and Cortisone (Tivey 1954; Hansen, 1950) .
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Uric acid excretion appears to be an indication of the effectiveness of drugs which either actually kill cells or cause a decrease in
their proliferation by metabolic competitive inhibition (Tivey, 1954).
A.

PHARMACOLOGY
The toxicity of 6-MP has been investigated by Meeker et al . , (1959);

Phillips et al., (1953); Clark et al . , (1953) and others.

The patholog-

ical effects in mice included hepatic necrosis, hypoplasia of bone marrow,
involution of thymus, edema, and congestion in the intestinal epithelium.
The LD50 for multiple intraperitoneal injections was 100 mg/kg/day for
five days in mice.

The analog was slightly less toxic when orally admin-

istered (Phillips et al., 1954) .

Hamilton and Elion (1954) found that

toxicity often appears in man at a dosage of 2. 5 mg/kg of body weight/day.
Experimental studies conducted by Lewis et al., (1969) demonstrated
that male chicks can tolerate oral administration of 1200-1800 mg/kg of
body weight/day of 60MP.

Clark et al. , (1953) found that a single dose

of 100 mg/kg of 6-MP can be tolerated by cats.

At this level, anorexia,

weight loss, vomiting, diarrhea, jaundice and leukopenia were observed.
Phillips~ al., (1954) found similar symptoms in the dog; and in the
rabbit when 10 to 15 mg/kg of body weight/day of 6- MP was administered.
Comparisons of 6- MP with several closely related purine analogs
have revealed some common pharmacologic properties .

Like the purines,

adenine and probably 2-Chloro - adenine, 6-MP is in part oxidized in vivo
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and excreted as uric acid analogs.

In contrast to these purines, the

end product of 6-MP metabolism is 6-thiouric acid, and does not
crystallize in renal tubes to cause renal insufficiency, which is
prominent in animals given some of the other purine analogs (Phillips
~

al., 1954).

Whatever mechanisms are ultimately proposed, it is

clear at present that minor alterations in the structure of purines
can give rise to profound and unexpected changes in their pharmacologic effects (Phillips et al., 1954).

B.

CLINICAL APPLICATIONS
The main clinical application of 6-MP has been in acute leukemia

in children usually supplemented with hormone and antifolic acid
treatments (Sutton, 1962).

The toxic effects of 6- MP therapy in man,

other than bone marrow depression have rarely been reported (Einhorn
and Davidsohn, 1964).

Experimental studies have demonstrated that 6-MP

causes hepatic necrosis in animals (Phillips et al . , 1954); Clark et
!!.!,. ,1958).

Jaundice which occurs during the course of 6- MP therapy in

htnnans has been mentioned occasionally in the literature, Ruvidic et al . ,
(1961); Einhorn and Davidsohn (1964); and Burchenal et al., (1953).
6-MP is a representative of the folic acid antagonists, the purine
antagonists and steroid hormones which are active against acute leukemia
in both children and adults.

The antimetabolites, amethopterin and

6-mercaptopurine should be the main reliance of the chemotherapist,
Burchenal

~

al . , (1953).

The substitution of the mercapto group in the
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sixth position of the purine ring was found by Elion et al., (1962)
to be a promising way of producing substances inhibitory to microbial
growth whose action could be reversed by the administration of purines.
Clinical tests on leukemias and allied diseases confirmed the potency
of 6-MP and its relative lack of toxic effects at certain dosage levels
(Burchenal et al., 1953).
C.

METABOLISM
Studies on the absorption and metabolism of 6-MP in mice and man

have shown that the disposition of the drug by degradative processes
is rather extensive (Elion et al., 1954).

6-MP is metabolized in

the body to 6-thiouric acid as a sizeable portion of the urinary
excretion.

The obvious route from 6-MP to 6-thiouric acid is via

oxidation catalyzed by xanthine oxidase (Elion et al., 1959) and
Kraoff, (1957).

The administration of Xanthine oxidase inhibitor,

4-hydroxypyrazolo (3, 4-d) pyrimidine (HPP) concurrently with 6- MP
results in a marked decrease in the metabolic oxidation of 6-MP to
6-thiouric acid in the mouse and man.

The inhibition of metabolic

degradation by this method results in prominent potentiations of 6-MP
(Elion~ al., 1962).
Uric acid excretion appears to be an indicator of the effectiveness of drugs which either actually kill cells or cause a decrease in
their proliferation by metabolic competitive inhibition (Tivey, 1954) .
Uric acid is synthesized mainly in the liver of birds as indicated by
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Minkowski in 1886 and others since (Milroy 1904; Folin, Berglund and
Derick 1924); Benzinger and Krebs (1933); Edison, Krebs and Model
(1936).

It is now generally agreed that the kidney of birds is also

concerned in the synthesis of uric acid.

The liver of chickens and

pigeons produce hypoxantine, which is oxidized to uric acid by the
enzyme xanthine oxidase (Sturkie, 1954) .
D.

MECHANISM OF ACTION
It has been known for many years that the purines and pyrimidines

are not essential nutrients for the vast majority of living cells, yet
it is equally clear that they are essential metabolites for all forms
of life.

Higher organisms have extremely vigorous enzymes for breaking

down the purines and purimidines, chiefly in the liver (Potter, 1961).
It is known that the end product of purine metabolism in birds is uric
acid (Krebs, 1936).

It was shown that hypoxanthine was accwnulated in

the liver of some birds, which was further metabolized to uric acid
only in the presence of xanthine oxidase (Krebs, 1936).

Rypoxanthine

was increased by oxalacetate and glutamine (Orstrom et al., 1939), a
combination that would generate asparatic and glutamic acids.

Buchanan

and co-workers (1957) found by administrating labeled compounds to live
pigeons and isolating uric acid that the compounds given included
acetate, carbon dioxide, formate and the simple nucleic acid glycine.
The biosynthesis of purine ribonucleotides yields adenylic acid and
guanylic acids; the two major purines ribonucleosides 5-Monophosphate.

Adenine and guanine are converted to hypoxanthine and xanthine, which
is converted to uric acid (Greenberg, 1956) and Buchanan (1957.
6-MP, a purine metabolite was shown to inhibit mitosis in low
concentrations (Biesel, 1954) .

Hamilton and Elion (1962) found that

6-MP is largely incorporated into nucleic acid.

6- MP appears to

exert its force of action by competing with inosonic acid on the
pathway to adenylic acid (Hakala and Nichol, 1959).

Inosonic acid

was well known to be the deamination product of adenylic acid ( Potter,
1961).

This strategic position of inosonic acid , a single d e ~

pathway leads to it and from this compound, only minor changes are
needed to yield either adenylic acid or guanylic acid.

The terminal

cycle, by which guanylic and adenylic acids can both be converted
back to inosonic acid by different routes from the syntheti c pathways
provides a neat method for interconverting the two bases (Buchanan et
~ - , 1957) .
6-MP interference with nucleic acid synthesis is the means by
which it provides its cytostatic effect (Elion et al . , 1962) .
Experiments on the mode of reversal of the actions of 6-MP have dis closed that Co enzyme A, has been most effective in releacing the
cytostatic eff ects caused by 6-MP (Biesele, 1954) .

The antitumor

activity of 6-MP has been attributed to its conversion to an active
nucleotide by inosonic guanylic pyrophosphorylase (Brockman, 1960) .
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CHAPTER III
MATERIALS AND METHODS
GENETIC STOCK
Experimental animals were White Leghorn cockerels Hy-Line chicks
obtained from the Hy-Lay Hatcheries , Incorporated , Bryan, Texas.
The experimental chicks were housed in metal brooders; water
and feed were provided ad libitum.

The chicks were divided into

control and treated groups of twenty- five each.

The 6 -MP - Palladium

Complex-treated chicks received an average dosage level of 3168 mg/kg
of body weight per day, the 6-MP- treated chicks received an average
dosage level of 900 mg/kg of body weight per day, the 6-MP-(6-MP- Palladium Complex) treated chicks received 900 and 3168 mg/kg of body weight
per day respectively.

The controls received no treatment .

For all

groups treatment began five days after hatching and continued until the
tenth day.
Uric acid determinations on blood and liver were made at the
following intervals:

(1) At the end of a five-day treatment period;

(2) At the end of a ten-day treatment period and (3) At the end of a
five-day post -treatment period.

URIC ACID DETERMINATIONS
I.

Prepara tion of Samples
A.

Blood
Five chicks per group were sacrificed by decapitation for
each uric acid determination.

Blood from the cervical
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vessels was collected by pooling in centrifuge tubes and
allowed to stand at room temperature until clotting was
completed (2-3 minutes), then centrifuged 20 minutes at
2300-2400 r.p.m.

After centrifugation, serum was innne-

diately separated from all solid materials (blood cells,
etc.) and the solid materials were discarded.
B.

Liver
Liver was obtained by excision after blood samples had
been collected.

It was then weighed and frozen 3-4 days,

thawed, mixed with clinical sand and homogenated with
mortar and pestle using a volume of distilled water
equivalent to the weight of the liver, or the amount
required to obtain a specific dilution factor .

Centri-

fugation and separation of serum from solid materials
(liver tissue) was identical to that of blood.

All

solid material was discarded.
II .

Colorimetric Method
A.

Principle
The principle of this analysis for serum uric acid was
after Bittner, (1963) in which uric acid reduces a copper
chelate in an acetic acid medium, eliminating the customary interference from other reducing substances which
occurs in methods employing a carbonate medium and re-
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sulting in a highly specific test for uric acid.

No

cyanides were used.
A trichloroacetic acid filtrate or centrifugate was
added to an alcoholic sodium hydroxide solution to destroy
the reducing abilities of certain sulfhydryl compounds and
ascorbic acid.

A copper chelate in acetic acid was then

added to the alkaline mixture, and uric acid reduced the
cupric complex of the indicator in a final acid reduction
medium.

A yellow-orange color developed in less than ten

minutes, and the chromogenic response was stable for many
hours.

The response of the chromogen was linear through

at least 20 mg/100 ml using this procedure.

The color

developed was read in a spectronic 20 (Bausch and Lomb)
colorimeter at or near the wave length of maximum
absorption.
B.

Reagent's Kit Content
Bittner's Redox Reagent Solution, an acetic acid solution
of 2,9-dimethyl 1-1, 10-phenanthroline which is complexed
with cupric ion.
Alocholic Sodium ijydroxide , a mixture of half methyl
alcohol and half 1 .0 N sodium hydroxide.
Uric Acid Standard, an aqueous, slightly acid, uric
acid standard.

Formaldehyde is added as a preservative,
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and the pH adjusted to 5.5 with glacial acetic acid.

In

its final solution this is equivalent to a 5.0 mg per cent
standard solution.
Working Uric Acid Standard Solution,

To a clean 50.0 ml

volumetric flask was added exactly 1 . 0 ml uric acid
standard solution and 25 . 0 ml of 5 per cent trichloroacetic acid was added and filled to the mark with distilled water.

This solution is stable in plast ic at room

temperature for several days.

C.

Procedure
To 1.0 ml serum, 9 . 0 ml of freshly diluted 5% trichloroacetic acid (TCA) was added.

The precipitated protein

was allowed to remain in the TCA for fifteen minutes
before filtration to assure complete precipitation.
Whatman No . 40 filter paper was used in the filtration
process.

Five aliquots per experiment were analyzed.

Test tubes were labeled, and reagents were added as shown
below :

UNKNOWN
Filtrate

STANDARD

1 . 0 ml
1.0 ml

Working Standard

0.5 ml

5% TCA
Alcoholic Sodium Hydroxide
Distilled Water

BLANK

2.5 ml

2 . 5 ml

2 . 5 ml

0.5 ml

- 13-

(Tubes were agitated, allowed to stand for four minutes,
then the final reagent was added) .
Bittner's Redox
Reagent

2.5 ml

2.5 ml

2. 5 ml

All tubes were agitated and allowed to stand ten
minutes for complete color development.

The color was

stable as compared to the blank for several hours .

Color-

imetric readings were made at 454 mu using a Bausch and Lomb
spectrophotometer.
CALCULATIONS
1.

Dosage of 6-MP-Palladium Complex:
Dosage level= mg/capsule/day X 1. 76 (correction factor)
ave . wt. (kg)
or
Dosage level equals to : 1.76 X 3168 X ave. wt . of chick.

2.

Dosage of 6-MP:
Dosage level= mg/capsule/day
ave. wt. (kg)
mg/capsule/day= ave . wt. (kg) X mg/kg of body weight.

3.

Uric Acid Determination by Colorimetric Method:
Blood:
Optical density (O .D.) of Unknown (unk) X cone. of standard=
o.D. of Standard
cone. of unk.
Liver:
O.D. unk. X cone. of standard X correction factor (c,f) = unk.
O.D. std.
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Correction Factor:
Note:

The correction factor of 7 was determined by

reading various concentrations of liver homogenate in the
colorimeter.

Seven times the weight of liver was found

to be the dilution with water to maintain a linear color

response to 20 mg per 100 ml.
PREPARATION OF COMPOUND
Pure six-mercaptopurine sodium dichloro -di -6 -mercaptopurinato
palladate II monohydr ate (6 -MP - Pdx) was synthesized in our laboratory
according to the method of Kirschner et al . ,

(1966) .

Eighteen grams

of reagent grade palladium II chloride in 100 ml of water was added to
32 grams of 6 - mercaptopurine in 200 ml of 1 N aqueous NaOH and SO ml
of dioxane.

The resulting solution was heated on a water bath at

SO degrees C for one hour with continuous stirring .
The snuff-brown precipitate which formed was left at room
temperature for several hours , filtered, washed with water-dioxane
until no more color appeared and dried under vacuum.

The drug was

pulverized and weighed on the Mettler Balance in order to determine
the actual yield of the complex.
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CHAPTER IV

RESULTS AND DISCUSSION

Data were collected on a series of four experiments (100 chicks
each) designed to determine the induction capacity of 6-MP-Palladium
Complex (6-MP- Pdx) on uric acid suppression in 6-MP treated chicks.
All drugs were orally administered in gelatin capsule.
Figure 1, shows the relationship of 6-MP and 6-MP-Palladium Complex
on uric acid suppression in the blood of chicks receiving the drug for
ten days and a five day post treatment period,
The five day treatment period analysis of the blood uric acid concentrations were significantly higher for the 6-MP and 6-MP-Palladium
Complex treated chicks than that of the controls.
were 8,9 + .204 mg per 100 ml and 9.5

±

Uric acid levels

,548 mg per 100 ml for 6-MP

and 6- MP-Palladium Complex treated chicks; respectively.
value for the controls was 7.7

± . 133 mg

per 100 ml.

The uric acid

The differences

between these values were highly significant (P = • 01).
The uric acid levels in the blood from the fifth to the tenth
day treatment period were 11.0

± . 590

mg per 100 ml, 8.2

± .174 mg

per 100 ml for the 6-MP and 6- MP-Palladium Complex- treated chicks,
respectively.
per 100 ml.

The uric acid level of the controls was 8.4

± . 369

The differences between the 6- MP and 6-MP- Palladium

mg
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Fig. 1.

Effect of 6-MP-Palladium Complex, 6-MP and
6-MP (6-MP-Palladium Complex) on the Sera
Uric acid concentrations following five,
ten, and five-day post treatment periods
in male White Leghorn chicks.
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Complex-treated chicks were significant (P=.01).

The uric acid level

of the controls was higher than the 6-MP- Palladium Complex-treated
chicks.

This suggests that a delayed time period is required for the

6-MP-Palladium Complex to induce its uric acid suppression capacity, but
once established, levels may be lower or equal to that of the controls.
Following the five day post - treatment period that uric acid concentrations decreased in all treated chicks.

The 6-MP-treated chicks

uric acid concentration remained significantly higher than that of the
controls and the 6- MP-Palladium Complex treated chicks (P = .01) .

The

6-MP-Palladium Complex- treated chicks approached the level of the
controls (7.9 + . 210 mg per 100 ml and 7. 6

± . 175

mg per 100 ml)

respectively.
Figure 2, illustrates the effects of 6-MP and 6-MP- Palladium
Complex on liver uric acid concentrations in chicks treated for five,
ten and five day post treatment periods .
Analysis following the five day treatment period showed uric acid
concentrations of 106.0

± 1. 50

mg per 100 ml and 91.0

± 1. 09

mg per

100 ml for 6- MP and 6-MP- Palladium Complex-treated chicks, respectively.
The uric acid level of the chicks treated with 6 -MP was significantly
higher than that which was evi denced by the chicks treated with the
Complex.

The value for the controls was 82.0

±

1. 03 mg per 100 ml,

~hich was significantly lower than all of the treated chicks (P = .01) .
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=
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.
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C.

........
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Following the ten day treatment period uric acid analysis of the
liver showed an elevation in the concentration of uric acid in the
6-MP treated chicks, 115.0

± 2. 60

mg per 100 ml and a decreased con-

centration in the 6-MP- Palladium Complex-treated chicks 78 . 0
mg per 100 ml (P = . 01) .

± 2. 56

This latter value was insignificantly lower

than that of the controls ,6. 0

± 7.27) .

The chicks treated with 6-MP for five days and subsequently
treated with 6-MP- Palladium Complex showed a significant decrease in
liver uric acid for the ten day period of treatment.

The uric acid

level approached that of the controls.
Analysis following the five day post treatment periods showed an
over - all decrease in the liver uric acid concentrations.

The concen-

tration in 6-MP- treated chicks remained high (P = . 02) but lower than
that analyzed for the five through ten day treatment periods (P = . 01).
The 6-MP-(6-MP-Palladium Complex-treated chicks) approached the uric
acid concentration of the controls, 80.0
78.0

± 2. 30

± .604

mg per 100 ml and

mg per 100 ml respectively (P = .01).

The 6-MP-

Palladium. Complex-treated chicks uric acid concentration was lower
than the control, 75.0

± 1.52

mg per 100 ml and 78.0

± 2. 30

mg per

100 ml (P = .01) respectively.
Uric acid is mainly synthesized in the liver of birds as indicated
by Krebs, (1933); Minkowski, (1886); Milroy, (1904); Folin, Berglund and

Derick, (1924); Edison , Krebs and Model, (1936) therefore the liver uric
acid concentrations are expected to be higher than that of the blood.
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The liver of chickens and pigeons produce hypoxanthine, which is
oxidized to uric acid by the enzyme, xanthine oxidase (Sturkie, 1954).
This uric acid is readily conveyed to the excretory organs via the
blood, which can account for the increased serum uric acid at the
initial stages of treatment .

After ten days of treatment with 6-MP

Palladium Complex the uric acid concentrations in the serum and liver
decreases, which suggests that uric acid formation is being partially
inhibited somewhere between inosinic acid formation and xanthine
formation.
Large concentrations of uric acid are produced and excreted
during treatment of leukemia with antimetabolites, steroids and X- Rays
(Krakoff et al., 1961); Gerbandy, (1958); Watkin and Silver, (1958);
Phillips!:!_ al., (1954) and Elion et al., (1959) .

However, not all

antimetabolites will cause an increase in uric acid concentrations .
Folic acid antagonists block purine synthesis prior to inosinic
acid formation which results in a decrease in uric acid concentrations
and excretions (Krakoff et al., 1961).

Possibly the complex causes a

partial inhibition of some enzyme system prior to xanthine oxidase, or
there possibly could be a complete diversion of metabolites via other
pathways prior to uric acid formation, and it is conceivable that both
of the above mechanisms could be acting concurrently.
Figure 3, illustrates the relationship of growth rate of the
treated chicks and the controls for five, ten and five day post
treatment periods.
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Fig. 3.

Relationship of weight gain for five,
ten, and five - day post treatment
periods of 6-MP, 6-MP-(6-MP-Palladium
Complex) and 6-MP- Palladium Complex
treated Male White Leghorn chicks .
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Five day old chicks receiving 6-MP - Palladium Complex for ten days
experienced an increase in weight gain but not equal to that of the
controls for the treatment period, 77 grams and 98 grams respectively.
Following the five day post treatment, the 6-MP-Palladium Complextreated chicks gained weight comparable to that of the controls, 100
grams and 112 grams respectively.

The 6-MP-(6-MP-Palladium Complex-

treated) chicks showed a small weight gain, 61 grams for the 10 day
treatment period and a moderate increase following the post treatment
period, (97 grams) .

The 6-MP treated chicks experienced no weight gain

during the ten day treatment period (54 grams), and a moderate increase
following the post treatment period, 88 grams .

The low toxicity of

6-MP-Palladiuro Complex evidenced in this experiment is substantiated
by Lewis£!_ al., (1969) .

The weight gain of the 6-MP-Palladium Complex

treated chicks approached that of the controls .

6-MP administered

alone is known to be quite toxic in chicks at 1200-1800 mg/kg body
weight (Lewis et al., 1969) .

The reduced toxicity of 6-MP-Palladium

Complex at 3168 mg/kg of body weight per day levels, as compared to
the 6-MP treated chicks at 900 mg/kg of body weight per day was quite
significant .

Mortality of chicks receiving 6-MP-Palladium Complex

was less than that of the 6-MP and 6-MP-( -MP-Palladium Complextreated) chicks.
Macroscopic examination of the internal organs of the treated
Chicks revealed the following :

In the 6-MP treated chicks hepatic

-20-

necrosis, massive liver discoloration, enlargement and discoloration
of the gall bladder.

In the 6- MP-Palladium Complex-treated chicks,

only a slight discoloration of the liver was evidenced in a minority
of all chicks examined.

These observations were made with the con-

trols being used as standards.
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SUMMARY AND CONCLUSIONS

This investigation is the culmination of data collected on a series
of four experiments, designed to determine the induction of uric acid
suppression by 6-MP-Pallad~um Complex in 6-MP-treated chicks .

Five day

old White Leghorn cockerels received the drug orally on a daily basis
in gelatin capsules .
Uric acid suppression by 6-MP-Palladium Complex and 6-MP-(6-MPPalladium Complex) was significant 6-10 days following administration
of the drugs.

In contrast, the highest uric acid concentration was

evidenced in the 6-MP-treated chicks during this period.

After five

day post-treatment periods, uric acid concentration in the liver was
lower than that of the controls in the 6-MP-Palladium Complex-treated
chicks.
Under the conditions of the experiments the following conclusions
are made :
1.

6-MP-Palladiurn Complex has the capacity to suppress uric acid
production in the liver and sera of five day old male White
Leghorn chicks, previously treated with 6-MP for five days.

2.

6- MP-Palladium Complex is less toxic than 6-MP in male White
Leghorn chicks.

3.

6-MP-Palladium Complex may have some potential in the treatment of gout, based on its uric acid suppression capacity.

LITERATURE CITED

w.

1.

Andre, J. A., Schwartz, R. s., Mitus, W. J., and Dameshek,
(1962). Lymphoid response to skin homographs. II
Effects of antimetabolites. Blood, 19: 334-348.

2.

Bittner, D., Hall, s. and Mcclean, M. (1963). A method for
determination of uric acid using the cupric-henathroline indicator system.

3.

Biesele, J, J., (1954). Effects of 6-Mercaptopurine on
experimental tumors in tissue culture. Ann. New
York Acad, Sci., 60 : 228.

4.

Brockman, R. W., (1960). A mechanism of resistance to 6Mercaptopurine; Metabolism of Hypoxanthine and 6-MP
by sensitive and resistant neoplasm. Cancer Res.,
20: 643.

5.

Buchanan, Flask, Hartman, Levenberg, Lukens and Warren, (1957).
The chemistry and Biology of the purines, Churchill,
London p. 233.

6.

Burchenal, J. H., Murry, M. L., Ellison, R.R., Sykes, M. P.
and Tan, T. C., (1953). Clinical evaluation of a new
antimetabolite, 6-Mercaptopurine, in the treatment of
leukemia and allied diseases . Blood. 8: 965-999.

7.

Clark, D. A., (1953). 6-Mercaptopurine: Effects in mouse
sarcoma 180 and in normal animals, Cancer Res . , 13: 593.

8.

Clark, D. A., Elion, G. B., Hitchings, G. H., and Stock, C. C.,
(1959). An experimental design in combination
chemotheraphy. Ann. New York Acad. Sci., 76: 915-921 .

9.

Dameshek, W., Schwartz, R., (1958). Drug-Induced Immunological
Tolerance by Antimetabolites. Proc. Soc. Exptl. Biol .
Med., 99: 164.

10.

Dameshek, W., and Gunz, F., (1959). Chemotherapy of acute
leukemias in Cancer. Vol. 6, pp . 96-124, Butter
Worth, London and Washington, D. C.

11.

Edson, N. L., Krebs, H. A., and Model, (1936). The synthesis
of uric acid in the Avian organism: Hypoxanthine as an
intermediary metabolite. Biochem. J., 36: 1380.

12.

Einhorn, M., and Davidsohn, M. D., (1964). Repatotoxicity of
Mercaptopurines . Jour. of Amer. Mad. Assn., Vol. 188:
802- 806.

13.

Elion, G. B., Bieber, S. and Hitchings, G. H., (1954). Microbiological Effects of 6-Mercaptopurine. Ann. N. Y. Acad.
Sci. , 60: 200 - 206.

14.

Elion, G. B., Sandra Callahan, H. Nathan, S. Bieber, R. w. Rundles
and G. H. Hitchings, (1962). Biochemical Pharmacology.
12, 85-93.

15 .

Elion, G. B. , S. Mueler and G. H. Hitchings, (1959).
Chem. Soc., 81, 3042.

16.

Gerbandy, J. (1958). The urinary excretion of metabolites during
radiological cell destruction. British J. Cancer., 12:
275 .

17.

Greenberg, (1956).

18.

Hakala, M. T. and Nichol, C. A. (1959). Studies on the mode of
action of 6-Mercapopurine and its ribonucleoside on
marmnalian cells in culture. J. Biol. Chem., 234: 3224.

19.

Hamilton, L. and G. B. Elion, (1954). The fate of 6-Mercaptopurine in man. Ann. N. Y. Acad. Sci., 60: 304-314.

20.

Hansen, P. B., (1950) . Urethane therapy in leukemia with a few
remarks of the Relationship between uric acid excretion,
basal metabolism and blood counts : 349-356. International
Soc. of Renatology, 3rd Int. Nat. Cong., Cambridge, Mass.

21.

Kirshner, s., Y. K. Wei, D. Francis and J. G. Bergman, (1966).
Anticancer and Potential antiviral activity of complex
inorganic compounds. Jol. Med. Chem. 9: 369-372.

22.

Krakoff,

23.

Krakoff, I. H. (1961). Studies on purine metabolism in neoplastic
diseases. Med. Clin. North America., 45: 521.

Purine Metabolism.

Jal. Amer.

J. Biol. Chem., 219: 423.

r. H., (1957). Urinary uric acid excretion in leukemias.
The Leukemias:Etiology, Pathophysiology and Treatment.
p. 401, New York: Academic Press.

•

24.

Krebs, H. A. (1936). Metabolism of amino acids and related
substances, Ann. Rev. Biochem. 5: 247.

25.

Lewis, R. W., J. J. Woods and B. A. Rubin, (1960). Homograft
Reactions in the Chicks/ A rapid technique for
successful skin homografts, Poultry Sci., 39: 1270.

26.

Lewis, R. W., R. W. Mack, M. J . Dennis and J. J. Woods, (1969).
Leucopenia-Induction Capacity of 6-MP-Palladimn Complex
in the Chick. Pro. Soc. Exp. Biol. and Med. , 131:
1219-1222.

27.

Meeker, W.R. Jr., R. Condie, D. Weiner and R. Varco, (1959).
Prolongation of skin homograft survial in rabbits by
6-Mercaptopurines. Proc. Soc. Exp. Biol. Med. , 102: 459.

28.

Milroy, T. H., (1904). The Formation of uric acid in birds.
J. Physiol., 30: 47.

29.

Orstrom, and Krebs, (1939).

30.

Phillips, F. S. and S.S. Sternberg, (1953). Effects of 6-MP
in marmnals. Proc. Amer. Ass. Cancer Res., 1: 42.

31.

Phillips, F. S., S. s. Sternberg, L. Hamilton and D. A. Clark,
(1954). Toxic effects of 6-Mercaptopurines and related
Compounds. Ann. New York Acad. Sci., 60: 295.

32.

Potter, Van R., (1961). Nucleic acids outlines: Biosynthesis
of Purines and Pyrimidines. Burgess Pub. Co. Minn.

33.

Rosenthal, M. E., (1968). Pharmacology of immunosuppressive
agent. Pharmacological Evaluation Section-Research
Dept., Wyeth Lab., Randor, Pa.

34.

Rudivic, R. K., (1961). Toxic jaundice during the course of
6-Mercaptopurine therapy of three patiences lvi.th
leukemia. Srpski Arh. Celok Lek, 89: 889.

35.

Schwartz, R. s., (1966). Specificity of Immunosuppression by
Antimetabolites, Fed. Proc., 25: 165.

36.

Sidgwick, N. w., (1950). The Chemical Elements and their
Compounds. Vol. II, Oxford University Press, Amen
House, London, England,

J. Biochem., 33 : 990.

37.

Sturkie, (1954) . Avian Physiology.
York, N. Y.

Comstock Pub. Ass., New

38.

Sutton, W, W., (1962). Comparative evaluation of ACTH and
hydrocortisone used alone in sequence with 6-Mercaptopuri ne in the treatment of acite leukemia in children.
Cancer Chemotherapy Rept . , 16 : 157-159.

39.

Tivey, Harold, (1954). The Natural History of Untreated Acute
Leukemia. Annals of New York Acad. Sci., 60: 336- 337.

40.

Watkin, D. W., and Silver, R. T. , ( 1958). Nitrogen, Mineral s,
Uric Acid and Basal Metabolism Studies in a Case of
Adul t Leukemia. Amer. J. Med. , 24: 638.

41.

Wei, Y. K., (1960). Doctoral Disser. Wayne State University ,
Detroit , Mich. The Preparation of Complex Inorganic
Compounds of Potential Physiological Importance and a
Study of Their Physical and Chemical Properties and
Possible Anti - Carcinogenic and Antiviral Activity.

